Theravance Biopharma, Inc. TBPH
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
6/9
Piotroski F — financial health
0.96
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $107.5M | $105.9M | — | — | $296.7M |
| 2024 | $64.4M | -$56.4M | — | — | $175.5M |
| 2023 | $57.4M | -$55.2M | — | — | $213.0M |
| 2022 | $51.3M | $872.1M | — | — | $441.8M |
| 2021 | $55.3M | -$199.4M | — | — | -$338.6M |
| 2020 | $71.9M | -$278.0M | — | — | -$303.8M |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 0.96 (distress)
- Working capital / assets 0.783
- Retained earnings / assets -1.77
- EBIT / assets -0.007
- Equity / liabilities 1.571
Source: SEC EDGAR filings · CIK 0001583107 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.